LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

11.37 -6.42

Resumen

Variación precio

24h

Actual

Mínimo

11.11

Máximo

11.6

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

110.024

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+62.95% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.26%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-120M

248M

Apertura anterior

17.79

Cierre anterior

11.37

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 351 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Ganancias

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Ganancias

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Charlas de Mercado
Ganancias

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Charlas de Mercado
Ganancias

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Charlas de Mercado

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Charlas de Mercado

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Ganancias

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Charlas de Mercado

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Ganancias

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Ganancias

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Ganancias

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

62.95% repunte

Estimación a 12 Meses

Media 19 USD  62.95%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

149 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat